. . . . "investigational"@en . "An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties. [PubChem]"@en . . . "6-Aminocaproic acid"@en . . "Epsilon-Aminocaproic Acid"@en . "Take without regard to meals."@en . . . . . "For use in the treatment of excessive postoperative bleeding."@en . "* 169 mL/min"@en . . . . . "Epsicaprom"@en . . "A few cases of acute overdosage with intravenous administration have been reported. The effects have ranged from no reaction to transient hypotension to severe acute renal failure leading to death. The intravenous and oral LD₅₀ were 3.0 and 12.0 g/kg respectively in the mouse and 3.2 and 16.4 g/kg respectively in the rat. An intravenous infusion dose of 2.3 g/kg was lethal in the dog."@en . "approved"@en . "Aminocaproic Acid"@en . . . "6-aminohexanoic acid"@en . . . "Epsilcapramine"@en . . . . "AMINOCAPROIC"@en . "Acide aminocaproque"@en . . "Aminocaproic acid"@en . "60-32-2"@en . . . . . . . . . . . "Eaca"@en . . . . . . . . . "epsilon-Ahx"@en . . "Humans and other mammals"@en . . . "Absorbed rapidly following oral administration. In adults, oral absorption appears to be a zero-order process with an absorption rate of 5.2 g/hr. The mean lag time in absorption is 10 minutes. After a single oral dose of 5 g, absorption was complete (F=1)."@en . "\u00C1cido aminocapr\u00F3ico"@en . "Aminocaprons\u00E4ure"@en . . "Acidum Aminocaproicum"@en . "Renal excretion is the primary route of elimination, whether aminocaproic acid is administered orally or intravenously."@en . . . "Z"@en . . "Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. This consequently will reduce the amount of bleeding post surgery. Elevated plasma levels of lipoprotein(a) have been shown to increase the risk of vascular disease. Lipoprotein 9a)a has two components, apolipoprotein B-100, linked to apolipoprotein (a). Aminocaproic acid may change the conformation of apoliprotein (a), changing its binding properties and potentially preventing the formation of lipoprotein (a)."@en . "Ahx"@en . . . . . . . . . "Acide aminocapro\u00EFque"@en . . . . . . "Frantisek Mares, \"Process for producing caprolactam from 6-aminocaproic acid.\" U.S. Patent US3988319, issued August, 1955."@en . "* 23.1 \u00B1 6.6 L"@en . . "epsilon-Aminohexanoic acid"@en . . . . . . . . "Aminohexanoic acid"@en . . "EACA"@en . "The terminal elimination half-life is approximately 2 hours."@en . "AMICAR"@en . . "Caproamin"@en . . .